Form D · Biotechnology

Corino Therapeutics, Inc.

New York, NY · CIK 0001703341

Offering snapshot reported Apr 27, 2017 · SEC filing

Reported sold
$3.47M
Offering amount: $5M
Investors reported
27
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Apr 13, 2017
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 27, 2017Initial$3,474,000No comparison27SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$208K
Finders' fees
$0
Form D file number
021-285612
In addition to the cash commission above, Issuer also issued warrants to purchase a number of shares of Issuer's Common Stock equal to 5% of the aggregate amount of shares into which the Notes sold in the offering eventually are convertible.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Castle Hill Capital Partners, Inc.44131Castle Hill Capital Partners, Inc. · CRD 44131
ROTH Capital Partners15407ROTH Capital Partners · CRD 15407

Source: Form D, filed Apr 27, 2017. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Peter Barber Director
Daniel Di Pietro Director, Executive
Timothy Mc Inerney Director
Jay Moorin Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Peter Barber 57 West 57 Th Street 18 Th Floor
New York, NY, 10019